Physician profile
John Peter Halfen
NPI 1427533603
$3,326.65
in general payments reported to CMS, 2019-2025
27 companies · $21.99 in 2025
The $21.99 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $780 · 2023: $1,146 · 2024: $687 · 2025: $21.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.22 | 2021-2024 | |
| Novo Nordisk INC | $528.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $403.26 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $286.18 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $173.09 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $142.41 | 2021-2023 | M-M-R II, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $104.39 | 2021-2024 | |
| Glaxosmithkline, LLC. | $77.89 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $74.61 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $64.04 | 2023-2024 | Xarelto |
| Abbott Laboratories | $63.51 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $58.90 | 2023-2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $51.18 | 2022 | |
| Hologic Sales and Service, LLC | $50.90 | 2021-2024 | Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.19 | 2021-2024 | Xifaxan, Trulance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $44.75 | 2023-2024 | Azstarys |
| Currax Pharmaceuticals LLC | $43.71 | 2022-2023 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $28.29 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $27.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.73 | 2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $18.61 | 2023 | Inspire |
| Vbi Vaccine (Delaware) INC. | $16.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.37 | 2023 | Quviviq |
| Lucid Diagnostics INC. | $13.26 | 2022 | |
| Coopersurgical, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Halfen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.